Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression

Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression

Abstract Background Osteoporosis is a common phenomenon in HIV patients on tenofovir treatment, but its underlying mechanisms remain to be explored. Methods Quantitative real-time PCR was performed to analyze the expression of miR-302, miR-101, miR-145 and osteoclast-specific genes in the serum of H...

Full description

Bibliographic Details
Main Authors: Wei Lin, Xing-fu Li, Dong-cheng Ren, Meng Song, Li Duan, Jin-zhu Liu, Zi-rui Zhan
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Molecular Medicine
Subjects:
Osteoporosis
Zoledronic acid
HIV
RANKL
miRNA
Osteoclastogenesis
Online Access:https://doi.org/10.1186/s10020-021-00276-5

Internet

https://doi.org/10.1186/s10020-021-00276-5

Similar Items